[go: up one dir, main page]

UA105520C2 - Антитіла до людського tweak та їхнє застосування - Google Patents

Антитіла до людського tweak та їхнє застосування

Info

Publication number
UA105520C2
UA105520C2 UAA201112304A UAA201112304A UA105520C2 UA 105520 C2 UA105520 C2 UA 105520C2 UA A201112304 A UAA201112304 A UA A201112304A UA A201112304 A UAA201112304 A UA A201112304A UA 105520 C2 UA105520 C2 UA 105520C2
Authority
UA
Ukraine
Prior art keywords
antibodies against
against human
human tweak
tweak
binding
Prior art date
Application number
UAA201112304A
Other languages
English (en)
Russian (ru)
Inventor
Моніка Бенер
Хендрік Кньотген
Йєнс Нівьонер
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of UA105520C2 publication Critical patent/UA105520C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Винахід стосується антитіла, що зв'язується з TWEAK, фармацевтичної композиції, що містить це антитіло, та його застосування.
UAA201112304A 2009-04-02 2010-03-30 Антитіла до людського tweak та їхнє застосування UA105520C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09004905 2009-04-02
PCT/EP2010/002009 WO2010115555A2 (en) 2009-04-02 2010-03-30 Antibodies against human tweak and uses thereof

Publications (1)

Publication Number Publication Date
UA105520C2 true UA105520C2 (uk) 2014-05-26

Family

ID=40673340

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201112304A UA105520C2 (uk) 2009-04-02 2010-03-30 Антитіла до людського tweak та їхнє застосування

Country Status (23)

Country Link
US (3) US8093006B2 (uk)
EP (2) EP2414398A2 (uk)
JP (1) JP5596777B2 (uk)
KR (1) KR101344611B1 (uk)
CN (1) CN102369219A (uk)
AR (1) AR076020A1 (uk)
AU (1) AU2010233997A1 (uk)
BR (1) BRPI1014867A2 (uk)
CA (1) CA2756245A1 (uk)
CL (1) CL2011002452A1 (uk)
CO (1) CO6362025A2 (uk)
CR (1) CR20110462A (uk)
EC (1) ECSP11011362A (uk)
IL (1) IL214355A0 (uk)
MA (1) MA33097B1 (uk)
MX (1) MX2011010117A (uk)
NZ (1) NZ594347A (uk)
PE (1) PE20120577A1 (uk)
RU (1) RU2011143903A (uk)
SG (2) SG175005A1 (uk)
TW (1) TWI423815B (uk)
UA (1) UA105520C2 (uk)
WO (1) WO2010115555A2 (uk)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093006B2 (en) * 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
US9526846B2 (en) 2009-08-19 2016-12-27 Safety Syringes, Inc. Patient-contact activated needle stick safety device
WO2011097500A2 (en) 2010-02-04 2011-08-11 University Of Louisville Research Foundation, Inc. The tweak/fn14 system regulates skeletal muscle atrophy and regeneration
EA201300418A1 (ru) 2010-10-05 2013-09-30 Ф.Хоффманн-Ля Рош Аг Антитела к человеческому tweak и варианты их применения
WO2012122513A2 (en) 2011-03-10 2012-09-13 Omeros Corporation Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
CN104245738B (zh) 2012-04-05 2018-02-02 弗·哈夫曼-拉罗切有限公司 针对人tweak和人il17的双特异性抗体及其用途
JP2016000003A (ja) * 2013-04-19 2016-01-07 アステラス製薬株式会社 新規抗ヒトｔｗｅａｋ抗体
CN103399151A (zh) * 2013-06-24 2013-11-20 上海交通大学医学院附属瑞金医院 Cxcl8细胞因子检测试剂在制备甲状腺乳头状癌的诊断试剂中的应用
TWI843763B (zh) * 2018-10-31 2024-06-01 日商安斯泰來製藥股份有限公司 抗人類Fn14抗體
WO2025005938A1 (en) * 2023-06-26 2025-01-02 Memorial Sloan-Kettering Cancer Center Antibodies and antigen binding fragments thereof binding to chimeric receptors and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US7129061B1 (en) 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
TR199900903T2 (xx) 1996-08-07 1999-06-21 Biogen, Inc. Bir t�m�r nekroz fakt�r� ailesine ili�kin protein
EP0977887A2 (en) 1997-02-12 2000-02-09 Abbott Laboratories Member of the tnf family useful for treatment and diagnosis of disease
GB2339430A (en) 1997-05-21 2000-01-26 Biovation Ltd Method for the production of non-immunogenic proteins
ATE424459T1 (de) 1997-10-10 2009-03-15 Genentech Inc Apo-3 ligand
EA004590B1 (ru) * 1999-01-15 2004-06-24 Байоджен, Инк. Способ блокировки развития, или снижения тяжести, или проявлений заболевания "трасплантат против хозяина"
WO2000052926A1 (en) 1999-03-04 2000-09-08 Vision-Sciences Inc. Image sensor's unit cell with individually controllable electronic shutter circuit
GB9922069D0 (en) 1999-09-17 1999-11-17 Technolog Ltd Water distribution pressure control method and apparatus
AU1226301A (en) 1999-10-22 2001-05-08 University Of Pittsburgh Stem cell engraftment-enhancing cellular proteins and their uses
WO2001030429A1 (en) 1999-10-22 2001-05-03 Scimed Life Systems, Inc. Guided injection device
EP2298333A3 (en) 1999-12-20 2012-05-02 Immunex Corporation Tweak receptor
JP2004500844A (ja) 2000-05-08 2004-01-15 バイオジェン　インコーポレイテッド Ｔｗｅａｋアゴニストおよび血管形成因子を使用する、新血管新生を促進するための方法
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
CN103536916B (zh) 2002-04-09 2016-08-17 比奥根Ma公司 用于治疗tweak相关病症的方法
EP1811838A4 (en) 2004-11-08 2009-07-22 Univ Maryland TWEAK AS A THERAPEUTIC TARGET FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM IN CONNECTION WITH CEREBRAL OEDEM AND CELL DEATH
US7939490B2 (en) 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
EP1859277A4 (en) 2005-02-17 2010-03-17 Biogen Idec Inc TREATMENT OF NEUROLOGICAL DISORDERS
WO2006088890A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating stroke
EP1853312B1 (en) 2005-03-07 2014-12-10 Genentech, Inc. Methods and compositions for modulating tweak and fn14 activity
JP5339901B2 (ja) 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド 炎症傷害の処置および評価
WO2006130429A2 (en) 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
UA96416C2 (uk) * 2005-05-27 2011-11-10 Байоджэн Айдэк Ма Инк. Антитіло, яке зв'язується з tweak людини
US8093006B2 (en) * 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof

Also Published As

Publication number Publication date
AR076020A1 (es) 2011-05-11
US20100255008A1 (en) 2010-10-07
MA33097B1 (fr) 2012-03-01
WO2010115555A3 (en) 2011-01-06
KR101344611B1 (ko) 2013-12-30
SG175005A1 (en) 2011-11-28
WO2010115555A2 (en) 2010-10-14
CR20110462A (es) 2011-09-21
CN102369219A (zh) 2012-03-07
PE20120577A1 (es) 2012-05-23
US8883976B2 (en) 2014-11-11
RU2011143903A (ru) 2013-05-10
CA2756245A1 (en) 2010-10-14
TWI423815B (zh) 2014-01-21
SG10201404107SA (en) 2014-10-30
BRPI1014867A2 (pt) 2016-04-12
EP2597104A1 (en) 2013-05-29
ECSP11011362A (es) 2011-10-31
CL2011002452A1 (es) 2012-03-23
KR20110122868A (ko) 2011-11-11
US20120207750A1 (en) 2012-08-16
US8093006B2 (en) 2012-01-10
CO6362025A2 (es) 2012-01-20
US20120083015A1 (en) 2012-04-05
MX2011010117A (es) 2011-10-14
US8852887B2 (en) 2014-10-07
JP5596777B2 (ja) 2014-09-24
IL214355A0 (en) 2011-09-27
NZ594347A (en) 2012-09-28
AU2010233997A1 (en) 2011-08-18
TW201039847A (en) 2010-11-16
JP2012521771A (ja) 2012-09-20
EP2414398A2 (en) 2012-02-08

Similar Documents

Publication Publication Date Title
UA105520C2 (uk) Антитіла до людського tweak та їхнє застосування
MY159679A (en) Antibodies binding preferentially human csf1r extracellular domain 4 and their use
WO2009013543A3 (en) Targeted binging agents directed to kdr and uses thereof - 035
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
NZ600262A (en) Anti-her3 antibodies and uses thereof
WO2010037041A3 (en) Frizzled-binding agents and uses thereof
PH12013500356A1 (en) Engineered anti-tslp antibody
UA111818C2 (uk) Антитіло проти csf-1r
NZ601271A (en) Cd127 binding proteins
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
MY156458A (en) Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
MY177062A (en) Cd37-binding molecules and immunoconjugates thereof
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
UA100874C2 (en) Bivalent bispecific antibodies
MX2010005888A (es) Anticuerpos bivalentes biespecificos.
MX2010006396A (es) Anticuerpos bivalentes, biespecificos.
MX2010005682A (es) Anticuerpos bivalentes, biespecificos.
NZ600005A (en) Antibodies against human angiopoietin 2
MX2011011925A (es) Anticuerpos triespecificos o tetraespecificos.
NZ601615A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
MY173526A (en) Novel anti-?5?1 antibodies and uses thereof
HK1252863A1 (zh) 结合cd22的抗体分子
MX2012001262A (es) Inmunoglobulinas de dominio variable doble y usos de las misma.
MX2011011669A (es) Inmunoglobulinas de dominio variable dual y usos de las misma.